{"entity":{"id":"nct07070622","kind":"trial","name":"Planed Organ Preservation for Low Rectal Cancer After Neoadjuvant Chemotherapy (OPLAR)","aka":["OPLAR"],"tldr":"A phase 3 trial in colorectal cancer, run by West China Hospital, now recruiting.","summary":"Planed Organ Preservation for Low Rectal Cancer After Neoadjuvant Chemotherapy (OPLAR) is a phase 3, randomised interventional study registered as NCT07070622 by West China Hospital, with a registry enrolment figure of 186 participants, started 2024-11-01 and due to reach its primary completion in 2027-12-31. Interventions recorded: patients were assigned to receive TNT or iTNT management. Conditions listed: Rectal Cancer. Primary outcome: organ preservation rate，OPR. Colorectal eligibility wording from the registry: \"rectal adenocarcinoma confirmed by pathology and pMMR/MSS by immunohistochemistry and/or genetic testing;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07070622","url":"https://clinicaltrials.gov/study/NCT07070622"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07070622","phase":"3","setting":"Planed Organ Preservation for Early- and Intermediate-risk Low Rectal Cancer With Good Response to Neoadjuvant Chemotherapy","sponsor":"West China Hospital","enrolled":186,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07070622/","neighbours":{"cancer":[{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}